Market revenue in 2024 | USD 134.9 million |
Market revenue in 2030 | USD 429.1 million |
Growth rate | 21.7% (CAGR from 2025 to 2030) |
Largest segment | Gmp grade |
Fastest growing segment | GMP Grade |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | R&D Grade, GMP Grade |
Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 103.26% in 2024. Horizon Databook has segmented the China plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
The China plasmid DNA manufacturing market is expected to grow at a lucrative rate owing to advancements in the regulatory framework for cell-based research activities in the country. Furthermore, several biopharmaceutical companies are shifting their focus toward these advanced therapies with increasing investment in the field of cell & gene therapy.
This production facility has the ability to produce viral and non-viral forms of vectors, including AAV, plasmids, cell lines, lentivirus, and mRNA. This investment is expected to drive plasmid DNA manufacturing market in China.
For instance, in January 2021, vaccine Biopharmaceuticals Suzhou Co., Ltd and INOVIO signed licensing agreement to commercialize INO-800—a COVID-19 DNA vaccine—in greater China area, including Taiwan, Hong Kong, Macao, and Mainland China.
Horizon Databook provides a detailed overview of country-level data and insights on the China plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into China plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account